Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Respiratory system drug stubs
Ramatroban
Другие языки:

Ramatroban

Подписчиков: 0, рейтинг: 0
Ramatroban
Ramatroban.svg
Clinical data
Trade names Baynas
AHFS/Drugs.com International Drug Names
Routes of
administration		 Oral (tablets)
ATC code
  • None
Legal status
Legal status
  • Rx-only (JP)
Identifiers
  • 3-((3R)-3-{[(4-fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9H-carbazol-9-yl)propanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.159.668
Chemical and physical data
Formula C21H21FN2O4S
Molar mass 416.47 g·mol−1
3D model (JSmol)
  • C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
  • InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
  • Key:LDXDSHIEDAPSSA-OAHLLOKOSA-N

Ramatroban (INN) (also known as BAY u3405) is a thromboxane receptor antagonist.

It is also a DP2 receptor antagonist.

It is indicated for the treatment of coronary artery disease. It has also been used for the treatment of asthma.

It has been suggested that ramatroban, by modulating DP2 receptor, can reverse viremia-associated proinflammatory and prothrombotic processes which are similar to those induced by SARS-Cov-2. Hence, ramatroban, that has been used for the treatment of allergic rhinitis in Japan for the past two decades with a well established safety profile, merits investigation as a novel immunotherapy for the treatment of COVID-19 disease, although no clinical trial has yet been conducted.

Ramatroban was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer Yakuhin then marketed by Kyorin Pharmaceutical and Nippon Shinyaku Co., Ltd. under the trade name Baynas.

External links


Новое сообщение